SCHEMBL374442

SCHEMBL374442

CCOC(=O)COC1CCCCO1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.40
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
CYP2D6 P10635 1/20 0.35
CREBBP Q92793 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 2/20 0.34
HPGD P15428 2/20 0.34
ALDH1A1 P00352 1/20 0.34
NLRP3 Q96P20 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4284988 0.95 KMT2A (0.42) KMT2AMEN1MGAMGAASI
SCHEMBL20837278 0.88 MGAM (0.39) KMT2AMEN1MGAMGAASI
SCHEMBL21469084 0.88 KMT2A (0.44) KMT2AMEN1GAAHPGDALDH1A1
SCHEMBL20548080 0.86 KMT2A (0.41) KMT2AMEN1CYP2D6CREBBPCYP1A2
SCHEMBL22071027 0.86 KMT2A (0.49) KMT2AMEN1LMNAPOLB
SCHEMBL11076267 0.85 MEN1 (0.48) KMT2AMEN1LMNAPOLBALDH1A1
SCHEMBL25176578 0.84 KMT2A (0.44) KMT2AMEN1LMNAPOLBCYP1A2
SCHEMBL21068614 0.83 KMT2A (0.47) KMT2AMEN1
SCHEMBL9724933 0.83 MEN1 (0.42) KMT2AMEN1CREBBPHPGDALDH1A1
SCHEMBL8003850 0.82 MEN1 (0.48) KMT2AMEN1LMNAPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3374350-B1 HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS FORGE THERAPEUTICS INC (US) 2022-01-05 EP disclosed
EP-3374350-B1 HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS FORGE THERAPEUTICS INC (US) 2022-01-05 EP disclosed
CN-107207476-B Indole and azaindole derivatives and their use in neurodegenerative diseases 默克专利有限公司 2021-03-19 CN disclosed
US-20210078957-A1 SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS FORGE THERAPEUTICS, INC. 2021-03-18 US disclosed
US-20210078957-A1 SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS FORGE THERAPEUTICS, INC. 2021-03-18 US disclosed
US-10875832-B2 Substituted pyrimidines for treating bacterial infections FORGE THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
US-10875832-B2 Substituted pyrimidines for treating bacterial infections FORGE THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
US-10676433-B2 Indole derivatives and their use in neurodegenerative diseases MERCK PATENT GMBH (DE) 2020-06-09 US disclosed
US-10414735-B2 Substituted hydroxypyrimidinones for treating bacterial infections FORGE THERAPEUTICS, INC. (US) 2019-09-17 US disclosed
US-10414735-B2 Substituted hydroxypyrimidinones for treating bacterial infections FORGE THERAPEUTICS, INC. (US) 2019-09-17 US disclosed
WO-2007121453-A2 2-HYDROXY-1-OXO 1,2 DIHYDRO ISOQUINOLINE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-10-25 WO disclosed
WO-2007116412-A1 SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2007-10-18 WO disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 WO disclosed
US-6846915-B2 Hydroxypyridonate and hydroxypyrimidinone chelating agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-01-25 US disclosed
US-20050008570-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-01-13 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
EP-1423399-A2 HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-06-02 EP disclosed
US-20030095922-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-05-22 US disclosed
WO-2003016923-A2 HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-02-27 WO disclosed
US-3991053-A GROWTH AND FEED EFFICIENCY PROMOTERS PFIZER INC. (US) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008570-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents HAMP, GDI1, MPI KMT2A 2869/4885MEN1 843/4885MGAM 3286/4885
US-20210078957-A1 SUBSTITUTED PYRIMIDINES FOR TREATING BACTERIAL INFECTIONS DPYD, TYMP, UMPS KMT2A 2877/4885MEN1 3920/4885MGAM 1600/4885
US-10414735-B2 Substituted hydroxypyrimidinones for treating bacterial infections ALPI, HPGDS, SDHB KMT2A 3605/4885MEN1 3246/4885MGAM 604/4885
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 KMT2A 2995/4885MEN1 4658/4885MGAM 4835/4885
US-10676433-B2 Indole derivatives and their use in neurodegenerative diseases P2RX3, ADORA2A, P2RX7 KMT2A 2560/4885MEN1 4055/4885MGAM 3794/4885
US-10875832-B2 Substituted pyrimidines for treating bacterial infections UMPS, DPYD, TYMP KMT2A 2762/4885MEN1 4518/4885MGAM 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.